Does NAVITOCLAX Cause Malignant neoplasm progression? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with NAVITOCLAX. This represents 2.9% of all adverse event reports for NAVITOCLAX.
5
Reports of Malignant neoplasm progression with NAVITOCLAX
2.9%
of all NAVITOCLAX reports
3
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NAVITOCLAX?
Of the 5 reports, 3 (60.0%) resulted in death, 3 (60.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NAVITOCLAX. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does NAVITOCLAX Cause?
Sepsis (25)
Pneumonia (24)
Thrombocytopenia (21)
Febrile neutropenia (17)
Pyrexia (16)
Fatigue (14)
Anaemia (13)
Diarrhoea (13)
Acute kidney injury (12)
Off label use (11)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which NAVITOCLAX Alternatives Have Lower Malignant neoplasm progression Risk?
NAVITOCLAX vs NAXITAMAB-GQGK
NAVITOCLAX vs NEBIVOLOL
NAVITOCLAX vs NECITUMUMAB
NAVITOCLAX vs NEDAPLATIN
NAVITOCLAX vs NEFAZODONE